-
Fontolizumab Protein Design Labs.
francisj_dumont@yahoo.com
Protein Design Labs is developing fontolizumab, a humanized anti-interferon gamma monoclonal antibody, for the potential treatment of autoimmune diseases. By February 2003, the company was actively seeking to outlicense the development and commercialization rights to fontolizumab outside of the US and Canada.
PMID: 15912969 [PubMed - indexed for MEDLINE]
-
Related articles
-
Nuvion. Protein Design Labs.
Curr Opin Investig Drugs. 2002 Mar; 3(3):411-4.
[Curr Opin Investig Drugs. 2002]
-
ReviewTechnology evaluation: epratuzumab, Immunomedics/Amgen.
Curr Opin Mol Ther. 2003 Apr; 5(2):192-8.
[Curr Opin Mol Ther. 2003]
-
ReviewBertilimumab Cambridge Antibody Technology Group.
Curr Opin Investig Drugs. 2004 Nov; 5(11):1213-8.
[Curr Opin Investig Drugs. 2004]
-
ReviewISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D. 2007; 8(2):103-12.
[Drugs R D. 2007]
-
Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D. 2008; 9(3):197-202.
[Drugs R D. 2008]
- » See reviews... | » See all...
Cited by 1 PubMed Central article